Genmab — August 2014
-
Serious adverse reactions were reported in 45 percent of patients. The most common serious adverse reactions were pneumonia, acute renal failure, pyrexia, and congestive heart failure. Thirty seven of the 526 patients (7 percent) died during the studies. The most common causes of death, other than underlying disease, were cardiac (5 patients), end-organ failure (4 patients), and infection (4 patients)
-
Af analytikere igår var: Nordea, Danske Bank, Deutsche Bank, Carnegie, Bank of America, Jeffries og Kempen
-
Det var sq en fornøjelse at se den enorme interesse
-
så skal Jannsen vel betale 20bn$ for genmab?
-
vil lige igen opfordre jer alle til at stille spørgsmål til Q&A. Jo bedre spørgsmål vi leverer jo større chance for at genmab vil blive ved med at komme hos os
-
haha ja han virker lidt som en spøjs fætter, jeg kan heller ikke rigtigt tage hans voldsomme dialekt seriøs
-
Jeg syntes at høre Winkel tale om deres dialog med Gilead omkring Idelalisimab for kort tid derefter sige at det var gennem GSK de fik at vide at Idelalisimab forsøget var tæt på readout. Mon det var en fortalelses, idet Genmab ikke har officielle forbindelser til Gilead....
-
idelalisib?
-
ikke nogen grund til at gøre navnet sværere end det er
-
Og Gilead kalder det vidst for Zydelic nu i salgsøjemed :)....
-
Det er dog trods alt bedre Gazyvaro
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind